2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4705 Acute chest syndrome risk in adults with sickle cell disease receiving l-glutamine versus crizanlizumab with and without concurrent hydroxyurea: A multicenter real-world cohort study

Faith Reid, MD, Quan Do, MD2
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Virginia Commonwealth University, Richmond, Virginia, United States

Background
Acute chest syndrome (ACS) remains a major cause of morbidity and mortality in patients with sickle cell disease (SCD). Beyond hydroxyurea, L-glutamine (Endari) and crizanlizumab (Adakveo) are approved disease-modifying therapies with potential to reduce ACS risk. While randomized trials demonstrated a reduction in ACS with L-glutamine compared with placebo, evidence for crizanlizumab remains limited, and no direct comparative studies have evaluated ACS outcomes between these agents. We compared the incidence of ACS among patients receiving L-glutamine or crizanlizumab using a large real-world database.

Methods
We performed a multicenter retrospective cohort study using the TriNetX global health research network, which includes over 100 million de-identified patient records from 72 healthcare organizations. Adults (≥18 years) with HbSS sickle cell disease, a history of vaso-occlusive pain crises, and treatment with either L-glutamine or crizanlizumab were included. Patients with a history of ACS before treatment initiation were excluded. Analyses were stratified by concurrent hydroxyurea use. The primary outcome was ACS incidence at 1 and 2 years after treatment initiation. Baseline characteristics included age, sex, and hemoglobin level. Outcomes were assessed using Kaplan-Meier analyses, risk ratios (RR), hazard ratios (HR), and 95% confidence intervals (CI).

Results
Among patients receiving concurrent hydroxyurea (n=751), 460 received L-glutamine and 291 received crizanlizumab. Baseline characteristics were similar between the L-glutamine and crizanlizumab groups, including median age (33 vs. 30 years), male sex (41% vs. 40%), and mean hemoglobin (9.0±1.8 vs. 9.2±1.8 g/dL).

At 1 year, ACS occurred in 7.0% of patients receiving L-glutamine and 4.5% receiving crizanlizumab (RR 1.56, 95% CI 0.83-2.92; p=0.16). ACS-free survival was 92.3% versus 94.8%, respectively (HR 1.59, 95% CI 0.84-3.03; p=0.15). At 2 years, ACS occurred in 10.0% versus 7.2% of patients (RR 1.38, 95% CI 0.84-2.27; p=0.20), with ACS-free survival of 88.3% versus 90.8% (HR 1.39, 95% CI 0.83-2.33; p=0.21).

Among patients not receiving concurrent hydroxyurea (n=525), 381 received L-glutamine and 144 received crizanlizumab. Baseline characteristics were comparable, including median age (34 vs. 34 years), male sex (38% vs. 35%), and mean hemoglobin (9.7±2.1 vs. 9.9±2.0 g/dL). One-year ACS events were too infrequent for meaningful analysis. At 2 years, ACS occurred in 4.7% of patients receiving L-glutamine and 9.0% receiving crizanlizumab (RR 0.52, 95% CI 0.26-1.04; p=0.06). ACS-free survival was 93.8% versus 87.8%, respectively (HR 0.50, 95% CI 0.25-1.03; p=0.06).

Conclusions
In this large multicenter real-world study, both L-glutamine and crizanlizumab were associated with low ACS incidence over 1 and 2 years among patients receiving concurrent hydroxyurea, with no significant differences between treatment groups. Similarly, among patients treated without hydroxyurea, ACS incidence remained low, and no statistically significant difference was observed at 2 years. Although retrospective design and residual confounding limit causal inference, these findings suggest that crizanlizumab may provide ACS protection comparable to L-glutamine in routine clinical practice. Prospective comparative studies are warranted to confirm these observations.

Faith Reid, MD: No relevant conflicts of interest to declare.